NCTN Deep South Research Consortium
NCTN Deep South Research Consortium
批准号:
9439700
负责人:
MARY-ANN BJORNSTI
金额:
$43.67万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-16 至 2019-02-28
关键词:
AchievementAddressAlabamaAmerican College of Radiology Imaging NetworkAreaArkansasBasic ScienceCancer BiologyCancer ControlCancer PatientCancer and Leukemia Group BClinical Cancer CenterClinical InvestigatorClinical ResearchClinical TrialsClinical Trials Cooperative GroupClinical Trials NetworkCommunitiesCommunity OutreachComprehensive Cancer CenterCooperative Group ProgramCountryDeep SouthDetectionDiagnosisDoctor of MedicineEastern Cooperative Oncology GroupEnsureFacultyFosteringFundingGynecologic Oncology GroupHome environmentHospitalsInstitutionIntentionInternationalInvestigational TherapiesKnowledgeLeadLeadershipLouisianaMalignant NeoplasmsMalignant neoplasm of brainMalignant neoplasm of cervix uteriMalignant neoplasm of ovaryMalignant neoplasm of pancreasMentorsMinorityMinority ParticipationMississippiNamesNational Clinical Trials NetworkNational Surgical Adjuvant Breast and Bowel ProjectNewly DiagnosedOutcomeParticipantPatientsPhasePhysiciansPrincipal InvestigatorProcessQuality of lifeRadiation Therapy Oncology GroupRecording of previous eventsResearchResearch InfrastructureResearch PersonnelResearch TrainingScientistSiteSocioeconomic StatusSouthwest Oncology GroupTrainingTraining ProgramsTraining and InfrastructureTranslatingTranslational ResearchUniversitiesVisionWorkanticancer researchcancer carecancer clinical trialcancer health disparitycancer preventioncancer riskdemographicsethnic minority populationhealth disparityinterestmalignant breast neoplasmmemberminority healthminority scientistnext generationorganizational structurepatient populationpopulation basedprogramspublic health relevanceracial health disparityrecruitsurvivorshiptranslational scientist
中文摘要
描述(由申请人提供):阿拉巴马大学伯明翰分校(UAB)综合癌症中心(CCC)参与国家癌症相关临床试验合作小组计划的历史悠久。具体地说,UAB是GOG的创始成员之一,并一直是RTOG、ECOG和ACRIN的成员。CALGB、NSABP和SWOG。UAB CCC现在提交这份提案,成为NCI新重组的国家临床试验网络(NCTN)计划中的主要学术参与站点,特别是NCTN深南研究联盟。我们打算继续作为NCTN计划的主要贡献者,在美国,特别是在东南部,为NCTN计划提供科学领袖和临床试验参与者。为了实现这一总体愿景,我们提出了以下具体目标:1)进一步加强现有UAB CCC科学领导者对NCTN中心相关临床和翻译研究的参与,并在UAB CCC内部培养下一代NCTN中心科学领导者,以及2)进一步完善UAB CCC内的临床试验流程,以优化NCTN中心临床试验的潜在合格癌症患者和癌症风险患者的收益。我们在这份提案中详细描述了我们的NCI合作小组科学和患者应计贡献和成就,我们提议的联合体的领导和组织结构,以及我们打算如何利用现有的UAB CCC基础设施来实现我们的目标。我们还包括对我们建议的初级调查员招聘和指导计划的详细描述。
英文摘要
DESCRIPTION (provided by applicant): The University of Alabama at Birmingham (UAB) Comprehensive Cancer Center (CCC) has a long history of participation within the nation's cancer related Clinical Trials Cooperative Group Program. Specifically, UAB was a founding member of the GOG, and has been a member of RTOG, ECOG, ACRIN. CALGB, NSABP, and SWOG. The UAB CCC now submits this proposal to become a Lead Academic Participating Site, specifically named the NCTN Deep South Research Consortium, in the NCI's newly restructured National Clinical Trials Network (NCTN) Program. It is our intention to continue as a leading contributor of scientific leaders and clinical trial participants to the NCTN Program in th U.S. and particularly in the Southeast. To accomplish this overall vision, we propose the following specific aims: 1) To further enhance the involvement of existing UAB CCC scientific leadership in NCTN Center related clinical and translational research and to develop the next generation of NCTN Center scientific leaders within the UAB CCC, and 2) To further refine a clinical trials process within the UAB CCC that optimizes accrual of potentially eligible cancer patients and patients at risk for cancer to NCTN Center clinical trials. We include in this proposa a detailed description of our NCI cooperative group scientific and patient accrual contributions and accomplishments, a leadership and organizational structure for our proposed Consortium, and how we intend to utilize existing UAB CCC infrastructure to achieve our aims. We also include a detailed description of our proposed Junior Investigator Recruitment and Mentoring Program.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
与GOG 0174中使用的Dactinomycin方案相比,不同的甲氨蝶呤方案作为低风险妊娠滋养细胞肿瘤的第一线治疗更具成本效益吗?
DOI:
10.1016/j.ygyno.2016.10.038
发表时间:
2017-01
期刊:
Gynecologic oncology
影响因子:
4.7
作者:
[Miller CR, Chappell NP, Sledge C, Leath CA 3rd, Phippen NT, Havrilesky LJ, Barnett JC]
通讯作者:
Barnett JC
DOI:
10.1016/j.ejca.2016.05.008
发表时间:
2016-09
期刊:
EUROPEAN JOURNAL OF CANCER
影响因子:
8.4
作者:
[Bonner, James A., Giralt, Jordi, Harari, Paul M., Baselga, Jose, Spencer, Sharon, Bell, Diana, Raben, David, Liu, Joyce, Schulten, Jeltje, Ang, Kian K., Rosenthal, David I.]
通讯作者:
Rosenthal, David I.
DOI:
10.1016/j.gore.2017.05.006
发表时间:
2017-08
期刊:
Gynecologic oncology reports
影响因子:
1.2
作者:
[Toboni MD, Smith HJ, Dilley SE, Novak L, Leath CA]
通讯作者:
Leath CA
NCTN Deep South Research Consortium
-
批准号:10301677
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2020
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
NCTN Deep South Research Consortium
-
批准号:10361237
-
项目类别:
-
资助金额:$48.24万
-
财政年份:2019
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
NCTN Deep South Research Consortium
-
批准号:10159225
-
项目类别:
-
资助金额:$53.27万
-
财政年份:2019
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
NCTN Deep South Research Consortium
-
批准号:9888337
-
项目类别:
-
资助金额:$48.29万
-
财政年份:2019
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
NCTN Deep South Research Consortium
-
批准号:9236167
-
项目类别:
-
资助金额:$49.78万
-
财政年份:2014
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
2014 DNA Topoisomerases in Biology and Medicine Gordon Research Conference
-
批准号:8714782
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2014
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
CELLULAR RESPONSE TO TOPOISOMERASE I
-
批准号:8309812
-
项目类别:
-
资助金额:$26.7万
-
财政年份:2011
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
CELLULAR RESPONSE TO TOPOISOMERASE I
-
批准号:7313995
-
项目类别:
-
资助金额:$24.75万
-
财政年份:2007
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
SUMOylation and Cell Sensitivity to Top1 Poisons
-
批准号:7225898
-
项目类别:
-
资助金额:$28.09万
-
财政年份:2005
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
SUMOylation and Cell Sensitivity to Top1 Poisons
-
批准号:7087936
-
项目类别:
-
资助金额:$28.93万
-
财政年份:2005
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
SUMOylation and Cell Sensitivity to Top1 Poisons
-
批准号:7610916
-
项目类别:
-
资助金额:$0.66万
-
财政年份:2005
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
SUMOylation and Cell Sensitivity to Top1 Poisons
-
批准号:6989580
-
项目类别:
-
资助金额:$29.63万
-
财政年份:2005
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
SUMOylation and Cell Sensitivity to Top1 Poisons
-
批准号:7416724
-
项目类别:
-
资助金额:$28.09万
-
财政年份:2005
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
SUMOylation and Cell Sensitivity to Top1 Poisons
-
批准号:8041303
-
项目类别:
-
资助金额:$27.43万
-
财政年份:2005
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
2003 Molecular Therapeutics of Cancer Gordon Conference
-
批准号:6695927
-
项目类别:
-
资助金额:$0.2万
-
财政年份:2003
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
MECHANISMS OF SUPPRESSING CAMPTOTHECIN TOXICITY
-
批准号:6131164
-
项目类别:
-
资助金额:$29.36万
-
财政年份:1996
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
MECHANISMS OF SUPPRESSING CAMPTOTHECIN TOXICITY
-
批准号:2330970
-
项目类别:
-
资助金额:$23.82万
-
财政年份:1996
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
MECHANISMS OF SUPPRESSING CAMPTOTHECIN TOXICITY
-
批准号:6628318
-
项目类别:
-
资助金额:$29.36万
-
财政年份:1996
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
MECHANISMS OF SUPPRESSING CAMPTOTHECIN TOXICITY
-
批准号:2871890
-
项目类别:
-
资助金额:$22.37万
-
财政年份:1996
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
MECHANISMS OF SUPPRESSING CAMPTOTHECIN TOXICITY
-
批准号:2654219
-
项目类别:
-
资助金额:$24.77万
-
财政年份:1996
-
负责人:MARY-ANN BJORNSTI
-
依托单位:
海外基金